UNIGE document Scientific Article
previous document  unige:138760  next document
add to browser collection

Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy

Scholz, Hanne
Floisand, Yngvar
Mattsson, Jonas
Published in Stem cell reviews and reports. 2021, vol. 17, no. 1, p. 63-70
Abstract Nearly 500'000 fatalities due to COVID-19 have been reported globally and the death toll is still rising. Most deaths are due to acute respiratory distress syndrome (ARDS), as a result of an excessive immune response and a cytokine storm elicited by severe SARS-CoV-2 lung infection, rather than by a direct cytopathic effect of the virus. In the most severe forms of the disease therapies should aim primarily at dampening the uncontrolled inflammatory/immune response responsible for most fatalities. Pharmacological agents - antiviral and anti-inflammatory molecules - have not been able so far to achieve compelling results for the control of severe COVID-19 pneumonia. Cells derived from the placenta and/or fetal membranes, in particular amniotic epithelial cells (AEC) and decidual stromal cells (DSC), have established, well-characterized, potent anti-inflammatory and immune-modulatory properties that make them attractive candidates for a cell-based therapy of COVID19 pneumonia. Placenta-derived cells are easy to procure from a perennial source and pose minimal ethical issues for their utilization. In view of the existing clinical evidence for the innocuousness and efficiency of systemic administration of DSCs or AECs in similar conditions, we advocate for the initiation of clinical trials using this strategy in the treatment of severe COVID-19 disease.
PMID: 32696426
Full text
Research groups Création de tissus par bio-ingénieurie et régénération d'organes (1021)
Groupe Laurent Kaiser (virologie clinique) (668)
Laboratoire de biologie des tumeurs gynécologiques et du développement (927)
Autre: Juvenile Diabetes Research Foundation (grant# 3-SRA-2020-926-S-B)
(ISO format)
BERISHVILI BERNEY, Ekaterine et al. Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy. In: Stem Cell Reviews and Reports, 2021, vol. 17, n° 1, p. 63-70. doi: 10.1007/s12015-020-10004-x https://archive-ouverte.unige.ch/unige:138760

319 hits



Deposited on : 2020-07-31

Export document
Format :
Citation style :